Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.41 |
| ▸ | FOS | P01100 | 1/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405503 | 0.72 | NR3C1 (0.42) | FFAR4PTGDR | |
| SCHEMBL8023122 | 0.72 | FFAR4 (0.61) | FFAR4FFAR1PTGDRNPSR1 | |
| SCHEMBL6353967 | 0.72 | HPGD (0.48) | SLC6A4SLC6A2SLC6A3KCNH2HTR6 | |
| SCHEMBL657740 | 0.70 | ALDH1A1 (0.64) | FFAR4FFAR1NPSR1KCNH2 | |
| SCHEMBL9370964 | 0.70 | SPR (0.64) | NPSR1HTR6 | |
| SCHEMBL6500179 | 0.69 | FABP4 (0.57) | FFAR1HTR6 | |
| SCHEMBL11366139 | 0.68 | HTR6 (0.46) | FFAR4FFAR1NPSR1HTR6 | |
| SCHEMBL3555186 | 0.68 | NPC1 (0.51) | FFAR1KCNH2 | |
| SCHEMBL10781933 | 0.67 | GRIN1 (0.46) | EPHX2NR1H4KCNH2 | |
| SCHEMBL2960332 | 0.67 | JUN (0.55) | FFAR4FFAR1PTGDRFOSJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| CN-103183660-A | Chromane derivative used as TRPV3 (transient receptor potential vanilloid 3) conditioning agent | GLENMARK PHARMACEUTICALS SA | 2013-07-03 | — | — | CN | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2254879-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | EPHX2 2983/4885NR1H4 457/4885FFAR4 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.